Document:

Exhibit 10.1

 

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE
SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY
SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

SENIOR NOTE

 

	Principal Amount: Up to $___________	Dated as of March ___, 2022

 

Viveon Health Acquisition
Corporation, a Delaware corporation (the “Maker”), promises to pay to the order of ____________________ (the “Payee”)
the principal sum of ______________ Hundred Dollars ($____________) (the “Maximum Line Amount”), or if different from such
amount, the unpaid principal balance of the Loans (as defined below) as may be due and owing, in lawful money of the United States of
America, on the terms and conditions described below. All payments on this Promissory Note (this “Note”) shall be made
by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from
time to time designate by written notice in accordance with the provisions of this Note.

 

		1.	Loans. The Payee will make loans (each a “Loan” and collectively the “Loans”)
to the Maker, from time to time until the Maturity Date (as defined below), in such sums as the Maker may request by written notice to
Payee, which in the aggregate at any time outstanding will not exceed the Availability Amount (as hereafter defined) and which when funded
shall be reflected on Annex A hereto and initialed by an authorized signatory of Maker. The Maker may, from time to time until the Maturity
Date, prepay (without penalty or premium) the Loans hereunder. Maker shall not have the right to reborrow any portion of any Loans which
are repaid. For purposes hereof, the term “Availability Amount” means the Maximum Line Amount minus the principal amount of
all Loans prepaid or repaid hereunder.

 

		2.	Principal. The outstanding principal balance of this Note shall be payable on (a) December 31,
2022 or (b) promptly after the date (the “Maturity Date”) on which the Maker consummates an initial business combination
(a “Business Combination”) with a target business (as described in the Maker’s initial public offering prospectus
dated December 22, 2020 (the “Prospectus”)), whichever is earlier. The principal balance may be prepaid at any time
(without premium or penalty).

 

		3.	Interest. Interest on this Note (“Interest”) shall accrue on the outstanding
principal balance of this Note at a rate equal to 0.0% per annum.

 

		4.	Non-Convertible. This Note shall not be convertible into any securities of Make and accordingly
Payee shall not have the right to convert this Note into any securities of Maker.

 

     

     

    

 

		5.	Application of Payments. All payments shall be applied first to payment in full of any costs incurred
in the collection of any sum due under this Note, including (without limitation) reasonable attorney’s fees, , then to the payment
of accrued and unpaid interest and finally to the reduction of the unpaid principal balance of this Note.

 

		6.	Events of Default. The following shall constitute an event of default (“Event of Default”):

 

		(a)	Failure to Make Required Payments. Failure by Maker to pay the principal of this Note within five
(5) business days following the date when due.

 

		(b)	Voluntary Liquidation, Etc. The commencement by Maker of a proceeding relating to its bankruptcy,
insolvency, reorganization, rehabilitation or other similar action, or the consent by it to the appointment of, or taking possession by,
a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official) for Maker or for any substantial part of
its property, or the making by it of any assignment for the benefit of creditors, or the failure of Maker generally to pay its debts as
such debts become due, or the taking of corporate action by Maker in furtherance of any of the foregoing.

 

		(c)	Involuntary Bankruptcy, Etc. The entry of a decree or order for relief by a court having jurisdiction
in the premises in respect of Maker in an involuntary case under any applicable bankruptcy, insolvency or similar law, for the appointing
of a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) for Maker or for any substantial part of its
property, or ordering the winding-up or liquidation of the affairs of Maker, and the continuance of any such decree or order unstayed
and in effect for a period of 60 consecutive days.

 

		7.	Remedies.

 

		(a)	Upon the occurrence of an Event of Default specified in Section 5(a) hereof, the Payee may, by written
notice to Maker, declare this Note to be due immediately and payable, whereupon the unpaid principal amount of this Note, and all other
amounts payable hereunder, shall become immediately due and payable without presentment, demand, protest or other notice of any kind,
all of which are hereby expressly waived, anything contained herein or in the documents evidencing the same to the contrary notwithstanding.

 

		(b)	Upon the occurrence of an Event of Default specified in Sections 5(b) and 5(c), the unpaid principal balance
of this Note, and all other sums payable with regard to this Note, shall automatically and immediately become due and payable, in all
cases without any action on the part of the Payee.

 

		8.	Waivers. Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment
for payment, demand, notice of dishonor, protest, and notice of protest with regard to the Note, all errors, defects and imperfections
in any proceedings instituted by the Payee under the terms of this Note, and all benefits that might accrue to Maker by virtue of any
present or future laws exempting any property, real or personal, or any part of the proceeds arising from any sale of any such property,
from attachment, levy or sale under execution, or providing for any stay of execution, exemption from civil process, or extension of time
for payment; and Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof, on any writ
of execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by the Payee.

 

    2

     

    

 

		9.	Unconditional Liability. Maker hereby waives all notices in connection with the delivery, acceptance,
performance, default, or enforcement of the payment of this Note, and agrees that its liability shall be unconditional, without regard
to the liability of any other party, and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or
modification granted or consented to by the Payee, and consents to any and all extensions of time, renewals, waivers, or modifications
that may be granted by the Payee with respect to the payment or other provisions of this Note, and agrees that additional makers, endorsers,
guarantors, or sureties may become parties hereto without notice to Maker or affecting Maker’s liability hereunder.

 

		10.	Notices. Any notice called for hereunder shall be deemed properly given if (i) sent by certified
mail, return receipt requested, (ii) personally delivered, (iii) dispatched by any form of private or governmental express mail or delivery
service providing receipted delivery or (iv) sent by facsimile or (v) to the following addresses or to such other address as either party
may designate by notice in accordance with this Section:

 

If to Maker:

Viveon Health Acquisition Corp.

c/o Gibson, Deal & Fletcher, PC

Spalding Exchange

3953 Holcomb Bridge Rd., Suite200

Norcross, GA 30092

 

If to Payee:

 

[TBP]

 

Notice shall be deemed given on the earlier of (i) actual
receipt by the receiving party, (ii) the date shown on a facsimile transmission confirmation, (iii) the date reflected on a signed delivery
receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express mail or delivery service.

 

		11.	Construction. THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE
OF DELAWARE, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.

 

		12.	Jurisdiction. The courts of the State of Delaware have exclusive jurisdiction to settle any dispute
arising out of or in connection with this agreement (including a dispute relating to any non-contractual obligations arising out of or
in connection with this agreement) and the parties submit to the exclusive jurisdiction of the courts of Delaware.

 

    3

     

    

 

		13.	Severability. Any provision contained in this Note which is prohibited or unenforceable in any
jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating
the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable
such provision in any other jurisdiction.

 

		14.	Trust Waiver. The Payee has been provided a copy of the Prospectus. Notwithstanding anything herein
to the contrary, the Payee hereby waives any and all right, title, interest or claim of any kind (“Claim”) in or to
any amounts contained in the trust account in which the proceeds of the initial public offering (the “IPO”) conducted
by the Maker and the proceeds of the sale of securities in a private placement that occurred prior to the effectiveness of the IPO, as
described in greater detail in the Prospectus, were placed, and hereby agrees not to seek recourse, reimbursement, payment or satisfaction
for any Claim from the trust account or any distribution therefrom for any reason whatsoever. If Maker does not consummate a Business
Combination, this Note shall be repaid only from amounts remaining outside of the trust account, if any.

 

		15.	Amendment; Waiver. Any amendment hereto or waiver of any provision hereof may be made with, and
only with, the written consent of the Maker and the Payee.

 

		16.	Assignment. No assignment or transfer of this Note or any rights or obligations hereunder may be
made by any party hereto (by operation of law or otherwise) without the prior written consent of the other party hereto and any attempted
assignment without the required consent shall be void.

 

		17.	Further Assurance. The Maker shall, at its own cost and expense, execute and do (or procure to
be executed and done by any other necessary party) all such deeds, documents, acts and things as the Payee may from time to time require
as may be necessary to give full effect to this Note.

 

[The rest of this page is
intentionally left blank]

 

    4

     

    

 

IN WITNESS WHEREOF, Maker, intending to be legally
bound hereby, has caused this Note to be duly executed on the day and year first above written.

 

	 	 	VIVEON HEALTH ACQUISITION CORPORATION
	 	 	 
	 	By: 	 
	 	 	Name: 	 
	 	 	Title:	                      

 

Accepted and Agreed:

 

[NAME]

 

	By:	 	 
	 	Name: 	 	 
	 	Title:	                      	 

 

[Signature Page to Promissory Note]

 

 

5Exhibit 10.2

 

THESE SECURITIES AND ANY SECURITIES ISSUABLE UPON
THE EXERCISE OF THIS SECURITY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH
SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

VIVEON HEALTH ACQUISITION
CORP.

 

WARRANT

 

Issue Date: [    ], 2022

 

Viveon Health Acquisition
Corp., a Delaware corporation (the “Company”), hereby certifies that, for value received, [   ] or its registered
assigns (the “Holder”), is entitled to purchase from the Company up to a total of [    ] shares of Common Stock (each
such share, a “Warrant Share” and all such shares, the “Warrant Shares”), at any time and from time
to time from and after the consummation of an initial Business Combination until such date that is 49 calendar months after the Closing
Date, unless any such Warrant Shares are sold pursuant to Section 13, prior to such time (the “Expiration Date”), and
subject to the following terms and conditions:

 

1. Definitions.
As used in this Warrant, the following terms shall have the respective definitions set forth in this Section 1. Capitalized terms that
are used and not defined in this Warrant that are defined in the Subscription Agreement (as defined below) shall have the respective definitions
set forth in the Subscription Agreement.

 

“Business Day”
means any day except Saturday, Sunday and any day that is a federal legal holiday or a day on which banking institutions in the State
of New York are authorized or required by law or other governmental action to close.

 

“Closing Date”
means the date of the closing of an initial Business Combination.

 

“Common Stock”
means the common stock of the Company, $0.001 par value per share, and any securities into which such common stock may hereafter be reclassified.

 

“Exercise Price”
means $11.50 subject to adjustment in accordance with Section 9.

 

“New York Courts”
means the state and federal courts sitting in the City of New York, Borough of Manhattan.

 

     

     

    

 

“SEC” means
the U.S. Securities and Exchange Commission.

 

“Subscription Agreement”
means the Subscription Agreement, dated [ ], 2022, to which the Company and the original Holder are parties.

 

“Trading Day”
means (i) a day on which the Common Stock is traded on a Trading Market (other than the OTC QB), or (ii) if the Common Stock is not listed
on a Trading Market (other than the OTCQB), a day on which the Common Stock is traded in the over-the-counter market, as reported by the
OTCQB, provided, that in the event that the Common Stock is not listed or quoted as set forth in (i) and (ii) hereof, then Trading Day
shall mean a Business Day.

 

“Trading Market”
whichever of the New York Stock Exchange, the NYSE American, the NASDAQ Global Select Market, the NASDAQ Global Market or the NASDAQ
Capital Market on which the Common Stock is listed or quoted for trading on the date in question.

 

“Weighted Average Price” means,
for any security as of any date, the dollar volume-weighted average price for such security on the Trading Market during the period beginning
at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg. If the Weighted Average
Price cannot be calculated for such security on such date, the Weighted Average Price of such security on such date shall be the fair
market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market
value of such security, then such dispute shall be resolved pursuant to Section 15 with the term “Weighted Average Price”
being substituted for the term “Exercise Price.” All such determinations shall be appropriately adjusted for any share dividend,
share split or other similar transaction during such period.

 

2. Registration
of Warrant. The Company shall register this Warrant upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.

 

3. Registration
of Transfers. Subject to the transfer restrictions set forth in the Subscription Agreement, the Company shall register the transfer
of any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, with the Form of Assignment attached hereto as
Exhibit A duly completed and signed, to the Company at its address specified herein. Upon any such registration or transfer, a
new Warrant to purchase Common Stock, in substantially the form of this Warrant (any such new Warrant, a “New Warrant”),
evidencing the portion of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining portion
of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee
thereof shall be deemed the acceptance by such transferee of all of the rights and obligations of a holder of a Warrant.

 

    2

     

    

 

4. Exercise
and Duration of Warrants. This Warrant shall be exercisable by the registered Holder at any time and from time to time from and after
the Closing Date and through and including the Expiration Date, in whole or in part (but not as to fractional shares), by (i) delivery
of a written notice, in the form attached hereto as Exhibit B (the “Exercise Notice”), of the Holder’s
election to exercise this Warrant and (ii) if both (A) the Holder is not electing a Cashless Exercise (as defined below) pursuant to Section
4(a) of this Warrant, and (B) a registration statement registering the issuance of the Warrant Shares under the Securities Act of 1933,
as amended (the “Securities Act”), is effective and available for the issuance of the Warrant Shares, or an exemption
from registration under the Securities Act is available for the issuance of the Warrant Shares, payment to the Company, of an amount equal
to the applicable Exercise Price multiplied by the number of Warrant Shares as to which this Warrant is being exercised (the “Aggregate
Exercise Price”) by wire transfer of immediately available funds (a “Cash Exercise”). At 5:00 p.m., New York
City time on the Expiration Date, the portion of this Warrant not exercised or sold to the Company, pursuant to Section 13 hereof, prior
thereto shall be and become void and of no value.

 

(a) Cashless
Exercise. Notwithstanding anything contained herein to the contrary, the Holder may, in its sole discretion, exercise this Warrant
in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment
of the Aggregate Exercise Price, elect instead to receive upon such exercise the “Net Number” of shares of Common Stock determined
according to the following formula (a “Cashless Exercise”):

 

Net Number = (A x B) - (A x C)

B

 

For purposes of the foregoing formula:

 

A= the total
number of shares with respect to which this Warrant is then being exercised.

 

B= the Weighted
Average Price of the shares of Common Stock (as reported by Bloomberg) on the date immediately preceding the date of the Exercise Notice.

 

C= the Exercise Price
then in effect for the applicable Warrant Shares at the time of such exercise.

 

5. Delivery
of Warrant Shares.

 

(a) To
effect exercises hereunder, the Holder shall not be required to physically surrender this Warrant unless the aggregate Warrant Shares
represented by this Warrant is being exercised. Upon delivery of the Exercise Notice to the Company, the Company shall promptly (but in
no event later than three Trading Days after the Date of Exercise (as defined herein)) issue and deliver to the Holder, a certificate
for the Warrant Shares issuable upon such exercise, which, until such time as the Warrant Shares have been registered on a registration
statement with the Securities and Exchange Commission that has been declared effective (as contemplated by Section 12), shall contain
a restrictive legend. A "Date of Exercise" means the date on which the Holder shall have delivered to the Company: (i)
the Exercise Notice (with the then current Warrant Exercise Log attached to it), appropriately completed and duly signed, and (ii) if
such Holder is not utilizing cashless exercise to the extent permitted by this Warrant, payment of the Exercise Price for the number of
Warrant Shares so indicated by the Holder to be purchased.

 

    3

     

    

 

6. Charges,
Taxes and Expenses. Issuance and delivery of Warrant Shares upon exercise of this Warrant shall be made without charge to the Holder
for any issue or transfer tax, withholding tax, transfer agent fee or other incidental tax or expense in respect of the issuance of such
certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required
to pay any tax which may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or
Warrants in a name other than that of the Holder. The Holder shall be responsible for all other tax liability that may arise as a result
of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.

 

7. Replacement
of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and
substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of
evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity, if requested.
Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay
such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this
Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company’s obligation
to issue the New Warrant.

 

8. Reservation
of Warrant Shares. The Company covenants that it will at all times following the Closing Date reserve and keep available out of the
aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant
Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares which are then issuable and deliverable upon the
exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of Persons other than the Holder
(taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable
shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized,
issued and fully paid and nonassessable.

 

9. Certain
Adjustments. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from
time to time as set forth in this Section 9.

 

(a) Adjustment
upon Subdivision or Combination of Shares of Common Stock. If the Company at any time on or after the Issuance Date subdivides (by
any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater
number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of
Warrant Shares will be proportionately increased. If the Company at any time on or after the Issuance Date combines (by combination, reverse
stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Exercise
Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares will be proportionately
decreased. Any adjustment under this Section 2(a) shall become effective at the close of business on the date the subdivision or combination
becomes effective.

 

    4

     

    

 

(b) Other
Events. If any event occurs of the type contemplated by the provisions of Section 9(a) but not expressly provided for by such provisions
(including, without limitation, the granting of stock appreciation rights, phantom stock rights or other rights with equity features to
the holders of the Company’s equity securities), then the Company’s Board of Directors will make an appropriate adjustment
in the Exercise Price and the number of Warrant Shares so as to protect the rights of the Holder; provided, that no such adjustment pursuant
to this Section 9(b) will increase the Exercise Price or decrease the number of Warrant Shares as otherwise determined pursuant to this
Section 2.

 

(c) Par
Value. Notwithstanding anything to the contrary in this Warrant, in no event shall the Exercise Price be reduced below the par value
of the Company’s Common Stock.

 

(d) Record
Date. If the Company shall take a record of the holders of its Common Stock for the purpose of entitling them (i) to receive a dividend
or other distribution payable in Common Stock or (ii) to subscribe for or purchase Common Stock, then such record date shall be deemed
to be the date of the issue or sale of the shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend
or the making of such other distribution or the date of the granting of such right of subscription or purchase, as the case may be.

 

(e) Calculations.
All calculations under this Section 9 shall be made to the nearest cent or the nearest 1/100th of a share, as applicable. The
number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or for the account of the Company,
and the disposition of any such shares shall be considered an issue or sale of Common Stock.

 

(f) Notice
of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will promptly compute
such adjustment in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement
of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant
(as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment
is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company's Transfer
Agent.

 

10. No
Fractional Shares. No fractional shares of Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu
of any fractional shares which would, otherwise be issuable, the Company shall pay cash equal to the product of such fraction multiplied
by the closing price of one Warrant Share as reported by the applicable Trading Market on the date of exercise.

 

    5

     

    

 

11. Warrant
Holder Not Deemed A Stockholder. Except as otherwise specifically provided herein, the Holder, solely in such person’s capacity
as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company
for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such person’s capacity
as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any
corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise),
receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant
Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant
shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or
as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.

 

12. Registration
Rights. The Company agrees that no later than thirty (30) Trading Days after the closing of its initial Business Combination, it shall
use its best efforts to file with the SEC a registration statement on Form S-1 for the registration, under the Securities Act, of the
Warrant Shares. The Company will use its best efforts to cause the same to become effective and to maintain the effectiveness of such
registration statement until the expiration of the Warrants in accordance with the provisions of this Agreement. For the avoidance of
any doubt, unless and until all of the Warrants have been exercised on a cashless basis, the Company shall continue to be obligated to
comply with its registration obligations under the first two sentences of this Section 12.

 

13. Put
Option. Commencing on the date that is thirteen (13) months following the closing of the Business Combination, the Holder shall have
the right, in its sole and absolute discretion, but not the obligation (the “Put Right”), to cause the Company to purchase
all or a portion of the Warrants at a fixed price of $5.00 per Warrant Share. If the Holder desires to sell any of the Warrant Shares,
the Holder shall deliver to the Company a written, unconditional and irrevocable notice (the “Put Exercise Notice”)
exercising the Put Right and specifying the number of Warrant Shares to be sold by the Holder. The closing of any sale of the Warrant
Shares shall take place no later than ninety (90) days following receipt by the Company of the Put Exercise Notice. The Company shall
give the Holder at least five (5) days’ written notice of the date of the closing of the sale and purchase of the Warrant Shares
pursuant to the Put Exercise Notice (the “Put Closing Date”). The Company will pay the Put Purchase Price for the Shares
by wire transfer of immediately available funds on the Put Closing Date. Upon the consummation of the purchase and sale of the Warrant
Shares pursuant to the Put Exercise Notice, the Holder shall no longer have the right to exercise the Warrant to the extent of the number
of Warrant Shares sold on the Put Closing Date.

 

14. Notices.
Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing
and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered
via facsimile or e-mail (followed by facsimile) at the facsimile number or e-mail address specified in this Section prior to 5:30 p.m.
(New York City time) on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered
via facsimile or e-mail (followed by facsimile) at the facsimile number or e-mail address specified in this Section on a day that is not
a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the Trading Day following the date of mailing, if
sent by nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be
given. The addresses for such communications shall be: (i) if to the Company, to Viveon Health Acquisition Corp., c/o Gibson, Deal &
Fletcher, PC, Spalding Exchange, 3953 Holcomb Bridge Rd., Suite 200, Norcross, GA 30092, E-mail: [ ] Facsimile: [ ], attention: Chief
Financial Officer, (ii) if to the Holder, to the address, e-mail address, or facsimile number appearing on the Warrant Register or such
other address, e-mail address, or facsimile number as the Holder may provide to the Company in accordance with this Section or the Subscription
Agreement.

 

    6

     

    

 

15. Dispute
Resolution. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares,
the Company shall submit the disputed determinations or arithmetic calculations via email or facsimile within two (2) Trading Days of
receipt of the Exercise Notice giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company are unable
to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within five (5) Trading Days of such disputed
determination or arithmetic calculation being submitted to the Holder, then the Company shall, within two (2) Trading Days submit via
email or facsimile (a) the disputed determination of the Exercise Price to an independent, reputable investment bank selected by the Company
and approved by the Holder or (b) the disputed arithmetic calculation of the Warrant Shares to the Company’s independent, outside
accountant. The Company shall cause the investment bank or the accountant, as the case may be, to perform the determinations or calculations
and notify the Company and the Holder of the results no later than ten (10) Trading Days from the time it receives the disputed determinations
or calculations. Such investment bank’s or accountant’s determination or calculation, as the case may be, shall be binding
upon all parties absent demonstrable error. The expenses of the investment bank and accountant will be borne by the Company unless the
investment bank or accountant determines that the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares
by the Holder was incorrect, in which case the expenses of the investment bank and accountant will be borne by the Holder.

 

16. Miscellaneous.

 

(a) This
Warrant shall be binding on and inure to the benefit of the parties hereto and their respective successors and assigns. Subject to the
preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or
equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the
Holder and their successors and assigns.

 

(b) All
questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and
enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof.
Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of this Warrant and the transactions
herein contemplated (“Proceedings”) (whether brought against a party hereto or its respective Affiliates, employees
or agents) shall be commenced exclusively in the New York Courts. Each party hereto hereby irrevocably submits to the exclusive jurisdiction
of the New York Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any Proceeding, any claim that it is not personally subject
to the jurisdiction of any New York Court, or that such Proceeding has been commenced in an improper or inconvenient forum. Each party
hereto hereby irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a
copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof.
Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Each party hereto
hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding
arising out of or relating to this Warrant or the transactions contemplated hereby. If either party shall commence a Proceeding to enforce
any provisions of this Warrant, then the prevailing party in such Proceeding shall be reimbursed by the other party for its attorney’s
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Proceeding.

 

(c) The
headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the
provisions hereof.

 

(d) In
case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt
in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so
agreeing, shall incorporate such substitute provision in this Warrant.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK,

SIGNATURE PAGE FOLLOWS]

 

    7

     

    

 

IN WITNESS WHEREOF, the Company
has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.

 

	 	VIVEON HEALTH ACQUISITION CORP.
	 	 	 
	 	By:	 
	 	 	Name:	 
	 	 	Title:	 

 

    8

     

    

 

EXHIBIT A

 

VIVEON
HEALTH ACQUISITION CORP.

 

WARRANT
ORIGINALLY ISSUED [    ], 2022

WARRANT NO. [    ]

 

FORM
OF ASSIGNMENT

 

[To be completed and signed
only upon transfer of Warrant]

 

FOR VALUE RECEIVED, the undersigned
hereby sells, assigns and transfers unto ________________________________ the right represented by the above-captioned Warrant to purchase
____________ shares of Common Stock to which such Warrant relates and appoints ________________ attorney to transfer said right on the
books of the Company with full power of substitution in the premises.

 

Dated: _______________, ____

 

	 	
	 	(Signature must conform in all respects to name of holder as specified on the face of the Warrant)
	 	
	 	 
	 	Address of Transferee
	 	 
	 	
	 	 
	 	 

 

	SIGNATURE GUARANTEED:	
	 	 
	 	 

 

    9

     

    

 

EXHIBIT B

 

EXERCISE
NOTICE

VIVEON HEALTH ACQUISITION CORP.

 

WARRANT
DATED [    ], 2022

 

The undersigned Holder hereby irrevocably elects
to purchase _____________ shares of Common Stock pursuant to the above referenced Warrant. Capitalized terms used herein and not otherwise
defined have the respective meanings set forth in the Warrant.

 

(1) The
undersigned Holder hereby exercises its right to purchase _________________ Warrant Shares pursuant to the Warrant.

 

(2) The
holder shall pay the sum of $____________ to the Company in accordance with the terms of the Warrant.

 

(3) Pursuant
to this Exercise Notice, the Company shall deliver to the holder _______________ Warrant Shares in accordance with the terms of the Warrant.

 

(5) By
its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that (i) in giving effect to the exercise
evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (determined in accordance with
Section 13(d) of the Securities Exchange Act of 1934) permitted to be owned under Section 11 of this Warrant to which this notice relates
and (ii) it is an “accredited investor” as defined in Rule 501(a) under the Securities Act.

 

	Dated: ___________, ______	 	Name of Holder:
	 	 	 
	 	 	(Print)	 
	 	 	 
	 	 	By:	     
	 	 	Name:	 
	 	 	Title:	 
	 	 	 
	 	 	(Signature must conform in all respects to name of holder as specified on the face of the Warrant)

 

 

10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]